Pulmonary Drug Delivery from the Taifun Dry Powder Inhaler Is Relatively Independent of the Patient's Inspiratory Effort

Pitcairn, Gary R.; Lankinen, Tapio; Seppälä, Olli-Pekka; Newman, Stephen P.

doi:10.1089/089426800418622

Cited by 53 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both of these factors determine the ease with which the drug particles separate from the carrier particles during inhalation. In general, there is a reduction in lung deposition when the inspiratory effort is reduced, but this phenomenon is more marked for some inhalers [23] and less marked for others [24]. The multidose DPI used in this study contains a modified cyclone adjacent to the mouthpiece intended to aid particle desaggregation, and this may have been one factor that caused lung deposition to be independent of PIFR over the range 66 to 99 liters/min.…”

Section: Discussionmentioning

confidence: 99%

Lung Deposition of Aclidinium Bromide from Genuair®, a Multidose Dry Powder Inhaler

Newman¹,

Sutton²,

Segarra³

et al. 2009

Respiration

View full text Add to dashboard Cite

Background: Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for the treatment of chronic obstructive pulmonary disease (COPD). A next-generation multidose dry powder inhaler will be used for the delivery of aclidinium bromide. Objectives: To quantify whole lung deposition and regional lung deposition of aclidinium delivered by a multidose dry powder inhaler (Genuair®) in healthy subjects. Methods: A single dose (200 μg) of aclidinium bromide, radiolabelled with ^99mTc, was administered from the multidose dry powder inhaler at a targeted peak inspiratory flow rate (PIFR) of 90 litres/min in 12 healthy males (18–63 years). Gamma scintigraphy was used to quantify drug deposition in the lungs and oropharynx, as well as amounts retained in the inhaler and exhaled. The quantities of drug deposited in 6 concentric regions within the lungs were also determined. Results: The mean (± SD) PIFR was 79.0 ± 9.4 litres/min. The mean (± SD) percentages of the metered dose deposited in the whole lung and oropharynx were 30.1 ± 7.3 and 54.7 ± 7.2%, respectively. Deposition of aclidinium occurred in all 6 lung zones, but was highest in the most central zone. Conclusions: These results demonstrated that the multidose dry powder inhaler delivered aclidinium efficiently to the lungs. The whole lung deposition seen in this study is an indication of the likely whole lung deposition in COPD patients who inhale with similar PIFRs; however, further studies in patients are required to confirm this.

show abstract

Section: Discussionmentioning

confidence: 99%

Lung Deposition of Aclidinium Bromide from Genuair®, a Multidose Dry Powder Inhaler

Newman¹,

Sutton²,

Segarra³

et al. 2009

Respiration

View full text Add to dashboard Cite

show abstract

“…Most in vivo deposition studies with radiolabeled substances from dry powder inhalers teach that the deposition fractions in the central, intermediate and peripheral lung are very roughly one third of the total lung dose each [12][13][14]. This is more or less confirmed by deposition modelling studies with monodisperse particles of 3 μm inhaled at a moderate flow rate of 30 L/min [15] , although a good comparison in this respect is not possible as different lung regions are defined differently in these studies.…”

Section: Medicine Distribution Over the Entire Respiratory Tractmentioning

confidence: 99%

Pulmonary

Boer¹,

Eber²

2015

Practical Pharmaceutics

View full text Add to dashboard Cite

“…(29,30,33,48) These data are summarized by study in Figure 6A-D. The P/C values have been plotted in ascending order by volunteer to exemplify the rather dramatic effect of subject.…”

Section: Intersubject Variabilitymentioning

confidence: 99%

Understanding Penetration Index Measurements and Regional Lung Targeting

Clark

2012

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Radiolabeling of pharmaceutical inhalation aerosols began in the late 1970s. Since then, well over 100 studies have been published. These studies have documented lung deposition for all inhalation dosage forms; pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and nebulizers. They have provided valuable insight into the factors that influence total and regional lung deposition. Taken globally, this collection of data has recently been used to elucidate the influence of intersubject variability in head geometry on total lung deposition, showing good correspondence between theory and experiment. The analysis reported here is an attempt to take this data set one step "deeper" into the airways and understand the relationship between P/C ratio, derived from 2D imaging, and a more anatomically relevant biological distribution within the lung, 24-h clearance. Intersubject variability in regional deposition is also analyzed, although due to the sparse nature of the reported individual data only tentative conclusions can be drawn. Many different techniques for derivation and analysis of scintigraphic data have been reported in the literature, and this leads to some difficulties when performing the "meta-analyses" reported below. In this regard it is recommended that standardization of scintigraphy techniques should be a future goal.

show abstract

Pulmonary Drug Delivery from the Taifun Dry Powder Inhaler Is Relatively Independent of the Patient's Inspiratory Effort

Cited by 53 publications

References 20 publications

Lung Deposition of Aclidinium Bromide from Genuair®, a Multidose Dry Powder Inhaler

Lung Deposition of Aclidinium Bromide from Genuair®, a Multidose Dry Powder Inhaler

Pulmonary

Understanding Penetration Index Measurements and Regional Lung Targeting

Contact Info

Product

Resources

About